Special guest speaker on insurance October 25th at 9:00 PM EST!

Special guest speaker on insurance October 25th at 9:00 PM EST!

https://livesupportgroup.com/join

Click on above link to register for the meeting,  you will get a email with login instructions and special code

At Livesupportgroup.com, we strive to schedule speakers who are informative and timely.  With Insurance time right around the corner, we are proud for the 2nd year, to have Melissa Harrelson to our group on Wednesday, Oct 25th at 9:00 EDT pm.

 

Last year Melissa covered our questions and the changes we faced.

 

Melissa is very knowledgeable about all types of Insurance.  She will have time to share about the changes in Insurance for 2018.  After the intro, we will have time for Q and A, so have your questions ready.  

 

To be clear Melissa Harrelson is providing information as a community service.

 

Melissa Harrelson 

Insurance Agent specializing in life and health insurance since 2005.

BS in Human Resources

SHRM-CP

Licensed in AR, MO, OK life and health insurance.

Licensed in AR Healthcare Marketplace and Arkansas Works.

 

To attend there is no cost to members.  Please go to the join tab, fill in your email, your first name, last initial, and state. Confirm your membership in your email.   Then an email saying it is time to register for the meeting will come to your email. When you get your email to attend the event, fill in the information and a personalized link will come. One hour before the group you will get a reminder and a duplicate link for your convenience.

 

Indiana: needle exchange program.. 50 percent decrease in hepatitis C cases… CANCELLED .. BIBLE MADE THEM DO IT

An Indiana county just halted a lifesaving needle exchange program, citing the Bible

https://www.vox.com/policy-and-politics/2017/10/20/16507902/indiana-lawrence-county-needle-exchange

“People will absolutely die as a result.”

That’s how Chris Abert of the Indiana Recovery Alliance described the consequences of an Indiana county’s decision to stop a needle exchange program, which provides clean syringes to drug users in an effort to stop the spread of infectious blood-borne diseases like HIV and hepatitis.

Lawrence County commissioners’ reasoning: morals — and the Bible.

“It was a moral issue with me. I had severe reservations that were going to keep me from approving that motion,” County Commissioner Rodney Fish, who voted against the program, told NBC News. “I did not approach this decision lightly. I gave it a great deal of thought and prayer. My conclusion was that I could not support this program and be true to my principles and my beliefs.”

Before he cast his vote, Fish quoted the Bible — specifically, 2 Chronicles 7. It says, “If I shut up heaven that there be no rain, or if I command the locusts to devour the land, or if I send pestilence among my people; if my people, which are called by my name, shall humble themselves, and pray, and seek my face, and turn from their wicked ways; then will I hear from heaven, and will forgive their sin, and will heal their land.”

The empirical evidence, however, is on the needle exchange programs’ side. Abert said that it’s led to a 50 percent decrease in hepatitis C cases in Lawrence County so far this year. And multiple reviews of the evidence by the World Health Organization, the Centers for Disease Control and Prevention (CDC), and others have overwhelmingly supported needle exchanges.

Abert also argued that, if anything, the Bible teaches people to help those in need — exactly what a needle exchange program aims to do. “Christians believe their spiritual life is defined by how well they mirror Christ’s work in their daily lives,” he told me.

But that didn’t persuade commissioners, and they voted against the program.

Indiana’s troubled history with needle exchanges

This isn’t the first time needle exchange programs have proven controversial in Indiana.

In 2015, the southeastern part of the state suffered an HIV epidemic linked to the injection use of Opana, a prescription painkiller that’s been widely misused throughout the opioid crisis. Back then, state lawmakers — including then-Gov. Mike Pence — were opposed to a needle exchange program. It was only after the HIV epidemic worsened that Pence finally relented, allowing a needle exchange program in Scott County and later signing a law that lets counties set up needle exchange programs if they prove they have an epidemic.

But some counties have been resistant to the concept. NBC News reported that earlier this year, Madison County also shut down a needle exchange program due to pressure from the local prosecutor and Indiana Attorney General Curtis Hill, who was elected in November and opposes needle exchange programs.

Lawrence County was among the several that got permission for a needle exchange program. But this month, the program was halted pending reapproval from county commissioners. The law requires county approval for the program on an annual basis, even though the needle exchange does not use county or state funding.

On Tuesday, county commissioners voted against the needle exchange program. They heard from some members of the community who were opposed to the program, but Abert said that a drug court judge, academics, and health care providers also testified in favor of it. Ultimately, the commissioners sided with the opposition.

“It came down to morally, they’re breaking the law. I can’t condone that,” County Commissioner Dustin Gabhart said, according to Indiana Public Media. “Yes, it’s a problem. Yes, it needs to be resolved. I could not give them the tools to do it.”

Needle exchanges save lives. Period.

The common argument against needle exchange programs, echoed by Indiana officials, is that they enable drug use by providing people with the tools to use drugs. And, they claim, that may lead to more drug use.

The claims are not borne out by the evidence. A 1998 study from researchers at Johns Hopkins University found needle exchange programs generally reduced the spread of HIV without increasing drug use. A 2004 study from the World Health Organization, which analyzed two decades of evidence, produced similar results. A 2016 review of 15 studies by the CDC did as well.

As one example, the CDC noted that once Washington, DC, was able to implement a needle exchange program, an evaluation “showed a 70 percent decrease in new HIV cases among [injection drug use] and a total of 120 HIV cases averted in two years.”

This is, frankly, not a remotely controversial topic in the research: Needle exchange programs save lives. Many people are going to find ways to use drugs no matter what, and providing them with clean syringes at least eliminates some of the risk tied to that drug use.

Experts also say needle exchange sites can be crucial for linking people to addiction treatment. For an upcoming story, John Brooklyn, an addiction doctor in Vermont, told me that these programs can be critical for “meeting people where they are.” The idea is simple: Addiction treatment staff can drop by these needle exchange programs and offer their services. People won’t always take up the suggestion, but it helps reinforce that treatment is around and available.

Indiana’s story, though, shows the one thing holding back these successful public health programs: stigma that treats addiction as a moral failure instead of a medical issue.

So despite the public health evidence, officials will often cite moral objections to needle exchange programs. And more people will die as a result.

CVS Health Larry Merlo Works Magic By Taking Over The Drug Enforcement Agency

CVS Health Larry Merlo Works Magic By Taking Over The Drug Enforcement Agency”

Merlo pulls another rabbit out of his hat

Washington DC – CVS Health Executive Director, Larry Merlo and his cast of greedy shareholders and slick attorneys deal the United States Government another major blow in their efforts to combat crime. Special interest groups are organized groups of individuals sharing common objectives who actively attempt to influence policy makers. Corporations now spend about $2.6 billion a year on reported lobbying expenditures—more than the $2 billion we spend to fund the House ($1.18 billion) and Senate ($860 million). It’s a gap that has been widening since corporate lobbying began to regularly exceed the combined House-Senate budget in the early 2000s.

Today, the biggest companies have upwards of 100 lobbyists representing them, allowing them to be everywhere, all the time. For every dollar spent on lobbying by labor unions and public-interest groups together, large corporations and their associations now spend billions of dollars. Of the 100 organizations that spend the most on lobbying, 95 consistently represent business. Lobbying is nothing new to the U.S. Government and we have seen how special interest groups shape laws and trigger regulations for institutions like the Food and Drug Association (FDA) and we have seen how Big Pharma lobbied hundreds of health care bills in recent history, including the infamous Obamacare.

Larry Merlo of CVS Health and his train of corporate business lawyers has pulled-off the unthinkable, the biggest trick of all – They bought off the U.S. Government policing agencies designed to uphold the laws of the United States of America. This was a brilliant plan and most authorities consider this to be, one of the biggest tricks of the 21st Century. Everybody is talking about how Larry Merlo’s special interest group infiltrated the DEA, a Government entity funded by U.S. Tax dollars, and buy off 52 of their top lawyers and access thousands of DEA confidential records, including top secret investigative and active investigate files.

Larry Merlo and many corporate leaders feared for their safety as the lucrative DEA closed in on their dubious practices, which were designed and engineered to cripple the American public by introducing pharmaceuticals that they knew would cause harm. Big Pharma is not only controlling the DEA with U.S. tax dollars backing them and their agenda, they are also in control of the United States Congress – a public statement made by Senator Bernie Sanders. CVS passed Legislation to strip the DEA’s power to arrest corrupt Big Pharma executives passed with flying colors through the ranks of the Senate and Congress, surprisingly, without any objections by U.S. Government. The law to protect Big Pharma from prosecution should be repealed because corporate executives who bribed and paid-off government officials to provide protection for their own illegal crimes is not constitutional.

How Can You Make A Difference?

  • BECOME A MEMBER: Please support Doctors of Courage and our fight against unlawful Government abuse of doctors and healthcare providers nationwide. Your Membership helps to provide support for thousands of doctors who are being unlawfully jailed and stripped of their medical careers for treating patients with legal prescriptions.
  • JOIN THE FIGHT:Please support the American Pain Institute (API) at http://www.americanpaininstitute.org and get involve with their PAIN ADVOCACY WEEK, April 23rd – 30th, 2018, March On Washington and donate to help this cause. Thousands of Chronic Sickle Cell patients’ lives are being drastically reduced and they are dying because doctors are afraid to follow NIH treatment guidelines due to bigotry and government wrongful persecution of doctors in this country.
  • HELP MAKE CHANGE: Sign our petition requesting that Congress enact a Medical Board Civilian Police Review Committee law to deter medical board police and prosecutorial misconduct and hold these officials responsible for their actions. The most common crime against doctors made by the medical board police teams are “FALSE REPORTS” that police officers refer to as accusations. These are criminal actions by law enforcement and they are not held accountable for making false statements, perjury, and manufacturing evidence. A Civilian Police Review Committeewill help stop these senseless acts against healthcare providers and restore justice and constitutional rights.
SIGN / SHARE OUR PETITION to fight for doctors and nurses rights:

CLICK NOW – (: SAY NO TO DEA/MEDICAL BOARD POLICE

 

community pharmacists said they were serving patients with legitimate pain

DEA Chief: Pharma-Backed Law Hasn’t Hurt Agency’s Fight Against Opioids

The then-chief of the Drug Enforcement Administration assured Democratic Rep. Judy Chu the bill she cosponsored to take away a tool the agency used to prevent opioids from reaching the streets wouldn’t hinder the agency’s work.

A Washington Post and “60 Minutes” investigation revealed drug companies dumped millions into lobbying for the bill, the Ensuring Patient Access and Effective Drug Enforcement Act, which essentially stripped the DEA’s ability to suspend pharmaceutical companies that sent suspiciously large opioid shipments.

Chu of California received more than $31,000 from the pharmaceutical industry as of last year, according to the Center for Responsive Politics, but she told The Daily Caller News Foundation she was assured — in a meeting that took place five months after the law passed — the bill wouldn’t hurt the DEA’s work. (RELATED: Pharma Association Defends Law Weakening DEA’s Opioid Enforcement)

“I met with Chuck Rosenberg, the then-acting head of the DEA, who insisted that the bill would not negatively impact their work,” Chu told TheDCNF in a statement. “[I]t was my understanding that the DEA was closely involved in advising on drafting language that would not impact their mission,” she added. “I did not receive indication of opposition or concerns from within the DEA.”

Rosenberg also said “the legislation was unnecessary,” Chu recently wrote in a letter to the House committees on Energy and Commerce and Oversight and Government reform, while requesting an investigation on the law impacted the DEA’s ability to combat the opioid crisis.

The DEA and the Department of Justice publicly opposed the original version of the legislation introduced in 2014. Agency officials didn’t object to the final version, but felt they were forced to accept a compromise on a bill that would ultimately pass, according to the Post/60 Minutes investigation.

“DEA felt this wasn’t a great solution, but was the best of the options offered to us, even if it did not fully address the concerns we had previously laid out for you,” Justice Department congressional liaison Jill Wade Tyson wrote in an email obtained by the WaPo/60 Minutes investigation.

The bill has created new challenges for the DEA, but investigators have started using new tools and haven’t “slowed down” the current acting-agency chief, Robert Patterson, recently said.

Chu also supported the bill to encourage the DEA to set better guidance for drug distributors to balance between ensuring patients can get their opioid prescriptions filled while preventing the painkillers from reaching the streets.

“I spoke with community pharmacists who said they were serving patients with legitimate pain, but were getting blocked with no explanation,” Chu said in her statement. “Their request was to receive consistent guidance from the DEA so they could avoid disruption for legitimate patients.”

“Community pharmacists must balance the work of combatting abuse with the work of ensuring those who need treatment have access to the medicine that can help,” she continued. “But after speaking with them, it was clear they needed better guidance in order to ensure they did both jobs appropriately.”

Lawmakers passed the bill unanimously, Chu noted.

New Jersey: CDC guidelines causing more under treatment of pain ?

Pain predicament: Opioid epidemic impacts prescription drug users with chronic pain

http://www.burlingtoncountytimes.com/news/local/pain-predicament-opioid-epidemic-impacts-prescription-drug-users-with-chronic/article_30557ceb-fc94-5d6e-b553-ae35ba5a185b.html

BURLINGTON TOWNSHIP — James Stewart remembers putting on his pads and running onto the grassy field to play football. The township resident said it was just over 20 years ago when he and his friends would still play competitively, despite being well into their 30s and 40s. Stewart has had a deep love for the game since childhood, and it’s stayed with him as he played in high school, college and then for fun.

But shortly after Stewart stopped playing, he began to have pain, mainly in his back, but also in his knees and other joints. He eventually underwent a two-part back surgery, as well as seven other surgeries in different areas to repair both bone and ligament damage.

 

“Most of the surgeries weren’t real heavy-duty stuff,” he said. “When I got to the back, it was a difficult surgery.”

Stewart, now 64, was sent home with two types of opioid painkillers in 2008 after the surgery to help deal with the pain. He had been warned about their addictive nature and took only one of them — 30 milligrams of oxycodone, as prescribed — to be able to move around without suffering.

“It was a two-part surgery, and I have chronic pain. It’s nerve on nerve. And I also need neck surgery. So I’m on medication just to try to have a decent day,” he said. “I’m not taking them to party. I don’t feel any ‘highness.’ All I feel is relief that I can go about a little bit of the day for a little while until it wears off.”

Stewart is one of at least 100 million Americans who suffer from chronic pain, according to a 2011 report from the Institute of Medicine. His original prescription said he could take one 30 mg pill four to six times a day, depending on his pain levels.

“I think I have a very good doctor, who did the best he could on my back, and I had to come in every time to get a prescription. There was no funny business,” he said. “I had to come in to see him personally to get a prescription. I never missed an appointment.”

However, just a few months ago in late April, Stewart said things changed. Instead of going to his doctor, he now goes to a pain management center to get his prescription filled, and his dosage amount was also reduced.

“(The pain management center) gave me a prescription for the 30 (mgs), and then when I came back the second time, I was informed, not asked, not, ‘How do you feel about this? What do you think about this?’ — I was told that now you’d be cut down to 15 mg, and that’s all I was told,” he said. “I was given a piece of paper that had this new guideline from the CDC.”

New guidelines

According to a statement from the U.S. Centers for Disease Control and Prevention, “Chronic pain is common, multidimensional and individualized, and treatment can be challenging for health care providers as well as patients.” In response to the critical need for consistent and current opioid prescribing guidelines, the CDC released the “Guideline for Prescribing Opioids for Chronic Pain.”

The purpose of the guidelines is to curb the overprescribing of opioid medication that led to the opioid epidemic, according to a statement from the CDC.

“Improving the way opioids are prescribed through clinical practice guidelines can ensure patients have access to safer, more effective chronic pain treatment, while reducing the risk of opioid use disorder, overdose and death,” the statement said. “Nearly 2 million Americans, aged 12 or older, either abused or were dependent on prescription opioids in 2014.”

In Burlington County, over 90 people have died from an overdose from January to July this year. Nationwide, more than 64,000 people died of an overdose in 2016, according to data from the CDC.

The guidelines focus on three main points: Determining when to initiate or continue opioids for chronic pain; monitoring the opioid selection, dosage, duration, follow-up and potential discontinuation; and assessing the risk and addressing the harms of opioid use.

Dr. Benjamin Duckles, a pain and spine specialist with Virtua who treats many chronic pain patients, said that since the new guidelines came out, he requires that all previous prescription histories and medical records are handed over to him so he can determine the best course of treatment for his patients.

“It depends on what treatment they’ve had prior to seeing me,” Duckles said. “The first and most important notion is to establish a diagnosis so we can discuss the history of their pain experience. I’m a big proponent of involving the patients in the process of understanding their pain or diagnosis.”

One of the new additions to the guidelines is that dosage recommendations for “exercising caution are lower than previous opioid prescribing guidelines.”

That was one of the issues Stewart had with the new restrictions.

“So the 30 (mgs), I could take no later than 8:30-9 in the morning, and that could last me, if i was lucky, until 2 (p.m.),” he said. “Then I would take another one about 3-4 (p.m.), and I was good. Now I take a 15 (mg), I don’t feel anything. I’m still bent over in the morning. They’re just not as effective as the 30 (mgs).”

Stewart said the reduction in dosage has dramatically affected his ability to get around like he used to.

“I’m just a little upset. I just want (my relief) back. I don’t do a whole lot. I’m not very active anymore; I can’t be,” he said.

Unintended consequences

 

In June, the American Academy of Pain Medicine released a “Future of Pain Care” resolution, noting that while the steps taken to address the opioid epidemic were helpful in many ways, they also adversely affected some patients who had used opioids safely and effectively.

“While the Centers for Disease Control drafted the Guideline for Prescribing Opioids for Chronic Pain to address the dramatic rise in opioid-related deaths, the document has, in some cases, had the unintended consequence of encouraging under-treatment, marginalization and stigmatization of the patients with chronic pain,” the resolution said.

Cassandra Badie, a Camden County resident, said she has felt this stigmatization as someone who suffers from neuropathy, stemming from her diabetes, which causes nerve damage in her feet and legs.

“You just don’t know what the feeling is to be treated like a drug dealer,” Badie said.

Some health officials caution that with all the focus on the opioid epidemic, other areas of the health care system are being ignored.

“All of the oxygen in the room is being used to address opioid addiction but not one of the primary causes, which is inadequate pain treatment,” Dr. Robert E. Wailes, a delegate with the American Academy of Pain Medicine, said in a statement attached to the resolution.

Duckles said he recognizes that opioids can be part of an effective treatment strategy for patients.

“One of the more important things we need to discuss is not forgetting that there are a lot of patients who have used opioids on a chronic basis for a long time and have done well,” he said. “Their pain has improved, and they’re able to do the things that they enjoy, whether that’s work or pleasure.”

Still, he cautioned against solely using opioid pills to treat pain. While each patient’s treatment is individualized, Duckles said he also employs other techniques, such as the use of anti-inflammatory prescriptions and physical therapy.

“My training taught me that the use of opioid therapy should never be done in isolation,” he said. “Opioid therapy alone doesn’t give them the best outcome.”

Patients like Stewart, however, said they at least would like to be included in the discussions that could have drastic effects on their lives.

“I’m not trying to cause a stink for anyone. I just want my medication not to be messed with and just to be talked to about it,” he said. “I’m not here to play any games. All I want to do is just have decent days.”

Australia: denial of proper pain management is INTERNATIONAL ?

Give Pain a Voice – You Tube Channel

 

 

Migraine Drug Used In ER May Not Be Best Option

Migraine Drug Used In ER May Not Be Best Option

https://www.news-line.com/PH_news28506_enews

A drug commonly used in hospital emergency rooms for people with migraine is substantially less effective than an alternate drug and should not be used as a first choice treatment, according to a study published in the online issue of Neurology®, the medical journal of the American Academy of Neurology.

“People go to US emergency departments 1.2 million times a year with migraine, and the opioid drug hydromorphone is used in 25% of these visits, yet there have been no randomized, high-quality studies on its use for acute migraine,” said study author Benjamin W. Friedman, MD, MS, of Albert Einstein College of Medicine in the Bronx, N.Y.

The study found that the drug prochlorperazine, given along with the drug diphenhydramine to prevent the side effect of restlessness, was superior to hydromorphone. Prochlorperazine is a type of drug called a dopamine antagonist. It blocks the release of dopamine, which is one of the many chemical messengers in the brain. The drugs were all given intravenously.

The researchers were also looking at whether the use of an opioid drug led to addiction in some people, with return visits to emergency rooms for repeat treatments.

“While this study demonstrates the overwhelming superiority of prochlorperazine over hydromorphone for initial treatment of acute migraine, the results do not suggest that treatment with IV opioids leads to long-term addiction,” Friedman said.

“In addition, the results should not be used to avoid the use of opioids for people who have not responded well to anti-dopaminergic drugs.”

The study involved 127 people who went to two emergency departments in New York with migraine. Half of the participants received hydromorphone and half received prochlorperazine. The researchers were looking to see how many people had sustained headache relief after 48 hours, which was defined as having a mild headache or no headache two hours after receiving the drug and maintaining that level for 48 hours without needing a rescue medication to stop the migraine.

The study was stopped after 127 people had enrolled because the 48-hour results showed that prochlorperazine was overwhelmingly superior to hydromorphone.

After 48 hours, 37 of the 62 people, or 60%, receiving prochlorperazine had sustained headache relief, compared to 20 of the 64 people who received hydromorphone, or 31 percent. In the emergency room, 31% of those who received hydromorphone asked for a second dose of the drug, compared to 8% of those who received prochlorperazine. Of those receiving hydromorphone, 36% requested other pain-reliever drugs, compared to 6% of the other group.

There was no difference between the two groups in how often they returned to the ER for migraine within one month of the treatment.

Friedman said that one limitation of the study is that participants were required to have not used opioids during the previous month and to have no history of addiction to prescription or illicit opioids, so the participants may have been at lower risk for problems with opioid use than the general population.

 

China already controls illegal fentanyl and 18 related compounds

China firms happy to sell killer opioid “weapon” to anyone in U.S.

https://www.cbsnews.com/news/china-sell-opioid-carfentanil-fentanyl-chemical-weapon-unrestricted-chinese/

SHANGHAI — It’s one of the strongest opioids in circulation, so deadly an amount smaller than a poppy seed can kill a person. Until July, when reports of carfentanil overdoses began to surface in the U.S., the substance was best known for knocking out moose and elephants — or as a chemical weapon.

Despite the dangers, Chinese vendors offer to sell carfentanil openly online, for worldwide export, no questions asked, an Associated Press investigation has found. The AP identified 12 Chinese businesses that said they would export carfentanil to the United States, Canada, the United Kingdom, France, Germany, Belgium and Australia for as little as $2,750 a kilogram.

Carfentanil burst into view this summer as the latest scourge in an epidemic of opioid abuse that has killed tens of thousands in the U.S. alone. In China, the top global source of synthetic drugs, carfentanil is not a controlled substance. The U.S. government is pressing China to blacklist it, but Beijing has yet to act.

“We can supply carfentanil … for sure,” a saleswoman from Jilin Tely Import and Export Co. wrote in broken English in a September email. “And it’s one of our hot sales product.”

The AP did not actually order any drugs, or test whether the products on offer were genuine.

China’s Ministry of Public Security declined multiple requests for comment.

For decades before being discovered by drug dealers, carfentanil and substances like it were researched as chemical weapons by the U.S., U.K., Russia, Israel, China, the Czech Republic and India, according to publicly available documents. They are banned from the battlefield under the Chemical Weapons Convention.

“It’s a weapon,” said Andrew Weber, assistant secretary of defense for nuclear, chemical and biological defense programs from 2009 to 2014. “Companies shouldn’t be just sending it to anybody.”

Carfentanil is 100 times more powerful than fentanyl, a related drug that is itself up to 50 times stronger than heroin.

Forms of fentanyl are suspected in an unsuccessful 1997 attempt by Mossad agents to kill a Hamas leader in Jordan, and were used to lethal effect by Russian forces against Chechen separatists who took hundreds of hostages at a Moscow theater in 2002.

The theater siege prompted the U.S. to develop strategies to counter carfentanil’s potential use as a tool of war or terrorism, according to Weber. “Countries that we are concerned about were interested in using it for offensive purposes,” he said. “We are also concerned that groups like ISIS could order it commercially.”

Later, dealers discovered that vast profits could be made by cutting fentanyls into illicit drugs. In fiscal year 2014, U.S. authorities seized just 8.1 pounds of fentanyl. This fiscal year, through just mid-July, they seized 295 pounds, Customs and Border Protection data show. Overdose rates have been skyrocketing.

The DEA has “shared intelligence and scientific data” with China about controlling carfentanil, according to Russell Baer, a DEA special agent in Washington.

“I know China is looking at it very closely,” he said. Delegations of top Chinese and U.S. drug enforcement officials met in August and September to discuss opioids, but failed to produce a substantive announcement on carfentanil.

China is not blind to the key role its chemists play in the opioid supply chain. Most synthetic drugs that end up in the United States come from China, according to the DEA.

China already has controlled fentanyl and 18 related compounds, but despite periodic crackdowns, people willing to skirt the law are easy to find in China’s vast, freewheeling chemicals industry. Vendors said they lied on customs forms, guaranteed delivery to countries where carfentanil is banned and volunteered strategic advice on sneaking packages past law enforcement.

“The government should impose very serious limits, but in reality in China it’s so difficult to control because if I produce 1 or 2 kilograms, how will anyone know?” said Xu Liqun, president of Hangzhou Reward Technology, which offered to produce carfentanil to order. “They cannot control you, so many products, so many labs.”

Last October, China added 116 synthetic drugs to its controlled substances list. Acetylfentanyl, a weak fentanyl variant, was among them. Six months later, monthly seizures of acetylfentanyl in the U.S. were down 60 percent, DEA data obtained by the AP shows.

Several vendors contacted in September were willing to export carfentanil but refused to provide the far less potent acetylfentanyl.

Seven companies, however, offered to sell acetylfentanyl despite the ban. Five offered fentanyl and two offered alpha-PVP, commonly known as flakka, which are also controlled substances in China.

Several vendors recommended shipping by EMS, the express mail service of state-owned China Postal Express & Logistics Co.

“EMS is a little slow than Fedex or DHL but very safe, more than 99% pass rate,” a Yuntu Chemical Co. representative wrote in an email.

EMS declined comment. A Yuntu representative hung up the phone when contacted by the AP and did not reply to emails. Soon after, the company’s website vanished.

 

The “SILENT KILLER”… not managed in >50% of adults – how many are under treated CPP’s ?

CDC: Control not achieved in more than half of US adults with hypertension

https://www.healio.com/cardiology/vascular-medicine/news/online/%7B0b2f8a78-bafe-48a6-bfd9-7750010bd446%7D/cdc-control-not-achieved-in-more-than-half-of-us-adults-with-hypertension

Less than half of U.S. adults with hypertension have their BP under control, according to a data brief released by the CDC’s National Center for Health Statistics.

“Despite progress in hypertension control that has been noted in the United States over the years, the goal of Healthy People 2020 (61.2% by 2020) has not been met,” Cheryl D. Fryar, MSPH, from the division of Health and Nutrition Examination Surveys at the National Center for Health Statistics, and colleagues wrote in the brief. “Currently just less than one-half of adults with hypertension have their hypertension under control (48.3%).”

Using NHANES survey data, the researchers found the overall prevalence of hypertension among U.S. adults from 2015 to 2016 was 29% and was similar in men and women (men, 30.2%; women, 27.7%). This prevalence grew more common with age, increasing from 7.5% among those aged 18 to 39 years to 33.2% among adults aged 40 to 59 years and 63.1% in those aged at least 60 years.

Although men had higher rates of hypertension than women among adults aged 18 to 39 years (9.2% vs. 5.6%) and aged 40 to 59 years (37.2% vs. 29.4%), men had lower prevalence of hypertension than women among adults aged at least 60 years (58.5% vs. 66.8%).

The researchers noted that hypertension prevalence was highest in non-Hispanic black adults (40.3%) compared with other races and ethnicities (non-Hispanic white adults, 27.8%; non-Hispanic Asian adults, 25%; Hispanic adults, 27.8%).

Among adults with hypertension, 32.5% of those aged 18 to 39 years had it controlled vs. 50.8% of those aged 40 to 59 years and 49.4% of those aged at least 60 years, according to the report.

Women were more likely than men to have their hypertension controlled (52.5% vs. 45.7%), especially in adults aged 18 to 39 years (62.6% vs. 15.5%).

Rates of hypertension control were higher in non-Hispanic white adults (50.8%) vs. non-Hispanic black adults (44.6%) and non-Hispanic Asian adults (37.4%).

According to the brief, there has been no significant change in hypertension prevalence among U.S. adults between 1999 and 2016. Although prevalence of controlled hypertension among those with hypertension rose from 31.6% in 1999-2000 to 53.1% in 2009-2010, it has not changed significantly since then, Fryar and colleagues wrote, noting the decline in controlled hypertension from 53.9% in 2013-2014 to 48.3% in 2015-2016 was not significant.

To believe or NOT TO BELIEVE… that is the question ?

I’ve Had to Swap My Stethoscope for a Magnifying Glass to Cope with Opioids

https://opmed.doximity.com/swapping-stethoscope-for-magnifying-glass-coping-with-the-responsibility-of-the-opioid-epidemic-61311957dc73

It should be simple, even if not so straight forward: If your patient is in pain, you treat them.

But what about a patient who’s been on opioids for years? How do you answer those who were led down the chronic opioid path by old school medicine, either rightly, or wrongly, so? Where do we draw the line?

Consider this example.

A patient walks in asking for a pain med refill. He’s had neck pain for years, and nothing has helped other than narcotics. His previous doctors gave him Percocets. Or Oxycontins. Or substitute whichever controlled substance you’d like here. What is my role in this given scenario, as his doctor? Classically, I’ve been trained to assess and treat the patient — simple as that.

But enter the dilemma of modern day medicine and the opioid epidemic. In this particular instance, as a PMD practicing today, I am expected to shed my doctor’s coat and stethoscope, while replacing them with the raincoat and magnifying glass of a sleuth. You can even add suspenders for dramatics. There’s only one problem: I have watched just a handful of episodes of Columbo in my youth and, while they were highly entertaining, I’m not quite ready to take on a role as understudy. I haven’t even rehearsed.

However, this growing epidemic expects me to do just that, to put on my detective gear and start interrogations.

But how can I do that? What if I miss an addict, and they in turn pass away of an overdose the following day? Or even worse, suspect ill of a patient and miss treating his real pain? And what of the patient’s opinion of me? Who would stay with a physician who constantly questions their honesty?

It’s a lose-lose.

The truth of it is that assessing for pain is tough. It’s subjective. If someone says they’re in pain, we often expect them to look like they’re in pain. But I know better, not only because I myself have held back pain, but also because I feel like I should trust my patients.

Then there’s the issue of physical examination. I use it as an investigational tool, but it certainly has its limitations. A patient who is seeking drugs can simply make up an ‘ouch.’ Think about it. You move the leg up, a patient utters in pain or grabs his backside. Who am I to judge if that grimace is real? It’s enough to have to scan through a myriad of possible diagnoses in my head, all by memory, gained through years of education and training, but to also have to call a bluff? Even the best of poker pros make mistakes. Plus, in real life, it’s easier to give people the benefit of the doubt. We want to believe them. I mean, sure, many of us in the field can recount instances in which patients theatrically put on a show to get what they want. But what about the instances that weren’t quite so obvious? I guarantee numerous Oscar-worthy performances could fool even the most seasoned of practitioners. And we are, after all, medical providers, not detectives.

But, this isn’t what I signed up for.

Let’s dissect the nature of filling a controlled substance request for a moment. Are you familiar with the procedure?

At some point during a 15 minute office visit, I must check on my patient’s previous and current usage of controlled substances by logging on to a separate databank on the web, a step mandated by the state. Once in it (after manual insertion of full name and date of birth), I peruse through a patient’s ‘record.’ Even grandma Louise must be subjected to such a search. This is no simple task and can take up quite a bit of time. I must then interpret information gained and determine if said patient is legitimately asking for the medication or possibly requesting their next easy fix. Followed, by the way, by a two-step verification process in which the medication is actually ordered. The details are lengthy and involve not only entering my system password once again but also providing a virtual ‘key,’ a 6-digit number I obtain by using an app installed on my iPhone.

*gulp*

Is this really what I signed up for when I took the Hippocratic Oath?

Yes, because I’ve promised to do no harm. If a patient is abusing, I should identify their addiction. I should help them with awareness, admission, and recovery.

But also, no. I want to heal, but I’m not quite ready for police work.

And when I do identify potential abuse, just how difficult can it be to tell someone they may have a problem? Extremely. How often does a patient actually admit to an addiction? Rarely. The very nature of coming in and asking for the mediation is the cycle of abuse in action. If I ever suggest there may be a problem, no one openly embraces my suspicion with open arms and a smile, or with a weeping confession. Unfortunately, this scenario is only encountered on Hollywood big screens or in the dreams of naive medical students. Addicts don’t admit. Addicts lash out. They deny. They are genuinely surprised. They threaten. They scream.

They even kill. Just read about Dr. Todd Graham of Indiana, 56 years old when he died for saying no to such a script.

It may seem easy, to anyone on the outside, to identify those who may be abusing. But no one walks into my office and says, “Doc, please give me oxy to feed my addiction,” or, “Send a prescription in so I can get back on the streets and sell. My supply is running low.”

No, I didn’t sign up for this. I signed up to go to work every day and to heal. To help identify illness. To help alleviate medical conditions. To have a good rapport with those who seek my advice. To come to work with a smile and to leave with a gratifying sense of achievement.

I signed up to heal.